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ABSTRACT 
DESIGN, FABRICATION, AND TESTING OF A 
MICROFLUIDIC SYSTEM FOR CARDIAC CELL CULTURE 
Mai-Dung Thi Nguyen 
June 17,2010 
Cardiovascular disease (CVD) is the leading cause of death in the United States and 
accounts for nearly 1,372,000 deaths each year. In addition, ~ 81 million Americans 
suffer from some form of CVD. Understanding the molecular basis of various 
manifestations of CVD requires cellular-level studies. However, current technologies for 
cell culture, fail to recreate the in-vivo environment where cells are subject to pressure 
and stretch as a consequence of normal hemodynamic loading and unloading. Therefore, 
to study cardiac cells with physiological relevance, the mechanical loading environment 
needs to be accurately replicated in-vitro. In order to create an appropriate platform for 
cardiac cell culture, a micro fluidic cardiac cell culture model (~CCCM) was designed 
and fabricated. This system consists of a pump, cell culture chamber, pneumatically 
actuated collapsible valve and a tunable resistance element in series. By varying the 
pump flow rate, valve closure frequency and the outflow resistance, various conditions 
associated with normal and dysfunctional heart function were recreated. A rat left 
ventricle heart muscle cell line (H9c2) was used to establish proof-of-concept and 
vi 
demonstrate the ability of the flCCCM to sustain cell culture under normal physiological 
conditions. Microscopic evaluation of these cells using phase contrast and 
immunofluoresence demonstrated that cells cultured within the I-lCCCM achieved an in-
vivo like phenotype in comparison to static unloaded controls. 
Keywords: microfluidics, cardiac, fabrication, cardiovascular disease, heart failure, 
PDMS thin membrane. 
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CHAPTER 1- CARDIOVASCULAR DISEASE AND THE HEART 
1.1. CARDIOVASCULAR DISEASE (CVD) 
The cardiovascular system consists of the heart, blood vessels (arteries, capillaries, and 
veins) and blood. The heart acts as a pump to circulate blood through the lungs to 
oxygenate, and flow through arteries to deliver oxygen and nutrients to the entire body. 
When the blood is delivered to tissues, the oxygen and carbon dioxide are exchanged . 
The deoxygenated blood is then returned to the heart via veins and [mally to the lungs, 
helping dispose carbon dioxide and other waste products. 
CVD collectively refers to abnormalities associated with various components of the 
cardiovascular system and covers over 60 disorders relating to the heart and vascular 
system. CVD is the leading cause of death in the United States and claims ~ 1,372,000 
lives each year [1-3] which is higher than the next 4 leading causes of death combined. 
Statistics from the American Heart Associate (AHA) indicate that ~ 81 million people or 
1I4th of the population suffers from some form of CVD in the United States. This 
includes high blood pressure ~ 74.5 million; coronary heart disease ~ 17.6 million; stroke 
~ 6.4 million; congenital cardiovascular defects ~ 650,000 to 1.3 million; and heart 
failure ~ 5.8 million. [1-2, 4] Based on the article: "Heart Disease and Stroke 2010 
Update" from AHA, it is estimated that the total indirect and direct cost due to CVD and 
1 
stroke in 2010 will be ~ 503.2 billion dollars placing a severe burden on the economy and 
diminishing the quality oflife for several thousands of people. [5-6] 
CVD can be classified into two major categories based on disorders of the heart or the 
vascular system. Disorders of the heart include conditions such as angina pectoris, 
arrhythmias, cardiomyopathy, congestive heart failure, and congenital heart disease. 
Disorders of the vascular system on the other hand include conditions such as aortic 
aneurysms, arteriosclerosis, high blood pressure, stroke, and transient ischemia. [4] 
Coronary heart disease is the most common type of CVD. It is a condition which fatty 
deposits build up inside the inner walls of coronary arteries, creating blockages of the 
arteries. These blockages reduce the blood flow, causing a pain or discomfort in the 
chest, heart failure (HF) and heart attacks. Similar to the coronary heart disease is 
atherosclerosis. In this disease, the arteries become thicker or harden; and the inner wall 
of the arteries becomes narrower due to the deposits of fat, cholesterol or other 
substances. This narrowed passage can block the blood flow and lead to heart attacks and 
strokes. Strokes occur when the blood vessels to the brain are occluded or broken. As a 
result, brain cells begin to die due to lack of oxygen and nutrition.[5-6] Stroke usually 
relates closely to high blood pressure, which happens when the pressure inside the vessels 
is higher than the normal range, which is about 120/80 mmHg. High blood pressure can 
cause HF, stroke, kidney failure, or other health problems. [7] The end stage for different 
CVDs is HF (Fig. I. I ) which occurs when the heart fails to pump sufficient blood through 
the body. The body, therefore, does not get enough oxygen and nutrients. HF develops 
slowly over time; and if not treated, can cause life-threatening conditions including 
2 
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Fig u re 1.1. Heart Failure is the end-stage of dysfunctional cardiovascular system existing for a 
long term. 
1.2. T REA T MEN T 0 F H EAR T F A I L U R E 
HF is a chronic disease; therefore, the treatment for HF needs lifelong management, 
which includes changes in living habits, medication, and assist devices to augment heart 
function. [8-9] The only cure for end- stage heart failure is total heart transplantation. 
Drug therapy is usually used for the initial stage of the HF. Depending on the stage and 
symptoms of HF, a single or combination of different medications are applied. The most 
common drugs used for treatment of HF include Angiotensin-converting enzyme (ACE) 
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inhibitors or Angiotensin II receptor blockers (ARBs), Digoxin (Lanoxin), Beta blockers, 
Diuretics, and Aldosterone antagonists. [1 0] Angiotensin-converting enzyme (ACE) 
inhibitors or Angiotensin II receptor blockers (ARBs) dilate the arteries and improve 
blood flow, therefore, decrease the workload on the heart. Digoxin (Lanoxin) helps to 
strengthen the contraction of heart muscle and slow the heart beat. Beta blockers reduce 
the heart rate and pressure. [10-11] Diuretics enhance urination frequency to keep from 
the fluid building up in the body, especially in the lung. Aldosterone antagonists help 
the heart work better. 
When the HF advances to a more serious stage, assist devices may be also used for the 
treatment. For example, implantable cardioverter-defibrillators are used for monitoring 
the heart rhythm. Cardiac resynchronization therapy or biventricular pacing are used to 
help the heart pump efficiently by sending timed electrical impulses to the heart's 
ventricles for contraction. Left ventricular assist device (LV AD) is used in a short term 
to assist those who are waiting for heart transplant or in a long term treatment for those 
have a weakened hearts or HF but cannot get a heart transplant.[12] LV ADs are designed 
as mechanical pumps to transport blood from left ventricle to the body. 
Heart transplant is applied for those who reach the end-stage of the HF. A healthier 
heart from a donor is replaced for the failing diseased heart.[13] However, people 
undergoing heart transplant face high risk of the rejection of the donor heart, infection, 
artery problems, medication side effect and potential high risk of cancer due to the 
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immunosuppresant medications.[13] In addition, due to the shortage of donors, people 
who need heart transplants experience long wait times. 
Heart transplant or LV AD are currently the only options for the end-stage HF. However, 
due to the lack of donors and the complications associated with immunosuppressive 
treatment as well as many high risks occurred during surgery, scientists and surgeons 
continue to search for new strategies to treat the HF. 
1.3. THE H EAR T 
The heart, through one organ, functions as two pumps coupled to one another in series. 
The right pump receives deoxygenated blood from entire body and pumps it to the lungs 
for oxygen-carbodioxide exchange while the left pump receives the oxygenated blood 
from the lung and then delivers this oxygenated blood to the entire body. As the result, 
the pressure in the right pump is lower than in the left pump. However, to perform 
pumping function, both the left and right pump needs to match their output volume. 
1.3.1. G ross anatomy of the heart 
Each side of the heart has a main pumping chamber (the ventricle), the holding chamber 
(the atria) and two valves to prevent back flow (Fig. 1.2.). The valve between the right 
atria and right ventricle is the tricuspid valve and between the left atria and left ventricle 
is the mitral valve.[14-15] These valves prevent the flow of blood back into the atrium 
when the ventricles contract. Pulmonic valve and aorta valve in the right and left 
ventricle prevent the blood from pulmonary artery and aorta flowing back to the right and 
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left ventricle when these ventricles relax. The two ventricles share a common wall and 













~----- Aortic Value 




Deoxygenated blood from the vena cava system flow back to the heart and is held in the 
right atria. When the tricuspid valve opens, the blood flows into the right ventricle. The 
blood in the right ventricle is pumped to the lung. Through the pulmonary artery, the 
oxygenated blood is brought to the left atria and then poured to the left ventricle when the 
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mitral valve opens. The left ventricle pumps the blood into the aorta to deliver blood 
throughout the body. Due to the pressure in the aorta being much higher than the 
pulmonary system, the left ventricle needs more force to pump; therefore, the muscle 
wall ofthe left ventricle is thicker than the right one. The walls of the atria are also much 
thinner than the ventricles. [14-15] 
1.3.2. Cellular organization 
Cardiac tissue is composed of three different major cell types: cardiomyocytes, cardiac 
endothelial cells, and smooth muscle cells. [13-15] Cardiomyocytes are the cells that 
make up the heart muscle and have the ability to contract spontaneously. To perform 
their function in synchrony, cardiomyocytes need to align in parallel and establish end to 
end cell-cell contacts (Fig.I.3.). Smooth muscle cells form a contiguous layer over the 
cardiomyocytes and finally a layer of endothelial cells line the myocardium providing 
shear protection. Besides these major cell types, cardiac tissue are also composed of 
cardiac fibroblast. Cardiac fibroblasts relate to heart remodeling, therefore, playa critical 
role in heart hypertrophy and heart failure. [16] 
1.4. W 0 R KIN G 0 F THE H EAR T 
Heart, consists of two atria and two ventricles, is the organ responsible for pumping 
blood throughout the body. The tension inside the heart due to the blood loading sends 
the mechanical then electrical signals inside the cells. This electrical signals travel 
through signal transduction pathway to stimulate the heart to pump. In response to this, 
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the chambers of the heart contract rhythmically, first both atria, then the ventricles. The 
working principle of the right pump side is similar to the left pump. 
Fig u re 1.3. Arrangement of cardiomycocytes in the cardiac muscle. 
(http://www.brown.eduICourses?BI0032Iadltstemlcardiac-muscle.gifj 
A pump cycle of the heart for the left pump can be also divided into two main periods: 
the systolic and diastolic periods. The systolic period starts when the mitral valve closes 
and muscle begins to contract until the aortic valve close after the blood in the ventricle is 
ejected to the aorta. The diastolic period starts when the aortic valve closes and the 
muscles begin to relax until the mitral valve closes after filling the blood from the atrium 
to the ventricle.[14-15, 17] 
The relationship between pressure and volume, the pump cycle of the heart especially for 
the left ventricle chamber can be divided into four phases: the ventricular filling or 
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diastole, the isovolumetric contraction, the ejection, and isovolumetric relaxation 
(Fig. 1.4.). [14-15, 17-18] During the ventricular filling phase, the relaxation of the heart 
muscles reaches to the maximum level. Therefore, when the blood from the atria 
continues to fill in the ventricle, the pressure of the ventricle goes up gradually and the 
blood volume is increased significantly, which is represented by phase 'a' on the 
pressure-volume loop. When the ventricle pressure reaches a certain level, the muscles 
contract.[18] The pressure in the ventricle at this point is higher than the atria, the mitral 
valve closes, but this pressure is not sufficient to open the aortic valve. Because all 
valves are closed, the pressure is increased dramatically while the volume remains the 
same, which is called the isovolumetric phase (phase b). At this point, the ventricle 
begins to contract until the pressure inside the ventricle chamber exceeds the aortic 
diastolic pressure; then the aortic valve opens, starting the ejecting phase (phase c). Once 
the aorta valve is opened, the blood inside the left ventricle is ejected to the aorta, causing 
a decrease in volume. However, the pressure still keeps increasing until it reaches to its 
peak, then decreases when the ventricle begins to relax, causing the closure of the aorta 
valve due to the pressure in the aorta larger than in the ventricle. In this relaxation, 
because of the closure of valves, the pressure inside the ventricle goes down quickly 
while the volume remains unchanged, creating a vertical line on the diagram B on the 
figure 4. When the pressure inside the left ventricle (LV) is lower than the left atria 
pressure, the mitral valve opens and the LV is filled with blood. At this point, the LV 
relaxes causing the pressure continues to fall. Once the relaxation of the L V stops, the 
pressure gradually increases when the volume increases. [14-1 5, 17-18] 
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Fig u re 1.4. Relationship between pressure and volume during the pump cycle of the heart. (A) 
Cardiac cycle diagram and (B) Pressure-Volume Loop. (a) Refilling phase, (b) Isovolumetric 
phase, (c) ejecting phase, and (d) Isovolumetric. 
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In normal condition, human heart rate is about 70±10 beats per minute (bpm), the stroke 
volume is about 60±10 mL/beat, left ventricular systolic peak pressure approximates of 
120±1O mmHg; and left ventricular end diastolic pressure ranges from 5-12 mmHg. [19-
20]. Stroke volume is the volume of blood ejected for each beat. 
1.5. CELLULAR RESPONSE TO MECHANICAL SIGNALS 
When a mechanical stimulus is applied to the extracellular matrix (ECM), the cells detect 
this mechanical stimulus Via mechanoreceptors such as integrins. These 
mechanoreceptors are located in the plasma membrane connecting the extracellular and 
intracellular regions of the cells, traducing the mechanical signals from outside to the 
inside the cell.(Fig.1.5.).[17, 21] Once the signal is transmitted inside of the cell, the 
signal triggers biochemical changes via signaling transduction pathway, enhances the 
formation of sarcomere, and alters directly the structure of the cytoskeleton. [17, 21] 
In cardiovascular system, two important signal transduction pathways are known: G-
protein and inositol triphosphate (IP3) pathways.[21] In the heart, the mechanical signals 
activate G-proteins to bind to the cell receptors. This binding complex activates the 
formation of cyclic AMP (cAMP); as a result, the concentration of Ca++inside the cell 
increased (via ion channels or from sarcoplasmic reticulum). [21] The increasing of Ca ++ 
promotes the contractility of the cardiomyocytes.[22] In IP3 pathway, once stimulated by 
mechanical signals, cell surface receptors bind to Gq proteins, enhancing the formation of 
inositol triphosphate IP3. This IP3 formation promotes the release of Ca ++ inside the cells, 
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which increases the contractility. [21] Therefore, any disorder on these pathways can alter 
the contractile ability of the heart muscle. 
Mechanical stimulus 
Integrins Cell-surface receptors 
Ion channels 
Bilayer 
cell membrane Nucleus Protein 
Fig u re 1.5. Transduction of mechanical stimulus at the cellular level. 
Cell-to-cell 
junction 
The length of sarcromere, a basic contractile unit of cardiomyocyte, is also affected by 
the mechanical stimulation.[23] When the muscle is stretched to a length greater than 
normal size, new sarcomere units are added rapidly at the end of the muscle fibers. [22, 
24] Unlike the skeletal muscle, sarcomere length in cardiac muscle does not change very 
much, and small change in sarcomere length can result large changes in tension 
generation.[23 , 25-26] Therefore, increasing the sarcomere length enhances the tension 
development, which affects the changes both in preload condition and the contractility of 
the heart. 
In addition, the deformation of the cytoskeleton can change the physical properties ofthe 
cells and distort the nucleus, as well as the biochemical and molecular events inside the 
cell, such as gene expression, transcription, translation and protein synthesis. This 
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change also affects physical and chemical communication between cells. Therefore, the 
structure inside the cell and the morphology of cell as well as the biochemical aspects of 
the cell are altered as a result of mechanical stimulus. 
To respond to these changes, the heart begins to remodel itself. The remodeling of the 
hearts causes to increase the number of fibroblasts, thickens the heart muscle wall, or 
enlargers the size of the hearts. [24, 27-28] These changes play critical roles in 
contractility of the cardiac tissue. If the mechanical stimulus insists, these modification 
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Fig u re 1.6. Physiological responses due to mechanical stimu Ius leading to heart failure. 
1.6. CONCLUSION 
CVD is a serious health problem and continues to claim several lives each year while also 
diminishing quality of life for several others. Current treatment options, though 
beneficial have several limitations. The heart is the central organ within the 
cardiovascular system and is extremely complex in terms of construction and function. 
This chapter serves to provide an overview of CVD and the heart structure and function. 
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CHAPTER 11- IN- VITRO MODEL SYSTEMS TO STUDY CARDIAC 
TISSUE 
2.1. NEED FOR CELLULAR-LEVEL STUDIES 
The human body consists of various levels of internal organization. Cells are the smallest 
functional units capable of sustaining themselves. Cells consist of various molecular 
constituents including bio-molecules like DNA, RNA and proteins. Cells are organized 
together to form tissue. Organs in the body responsible for specialized functions are 
made up of one or more types of tissue. Various organs and/or tissue in the body are 
organized together to form systems (Ex: Cardiovascular, Nervous, or Circulatory). 
Finally, an organism sustains life due to synergistic working of various systems within 
the body. Several mechanisms exist to provide feedback and maintain the body's 
functions within a tight range (homeostasis). 
The tradeoff between generation of highly specific molecular information and translation 
of that information in-vivo necessitates investigation at various levels of cellular 
organization (Fig. 2.1). Cell based studies are essential to provide highly specific 
information relating to molecular mediator and the targets for drug discovery and 
therapy. Analysis of purified or isolated cell populations free from surrounding cellular 
and extracellular constituents allows the investigation of sub-cellular mechanisms in great 







Figure 2.1. Specificity vs. Relevance plot. Human clinical studies are the most relevant but least 
specific whereas cellular level studies provide highly specific information but their relevance to 
human physiology is low. The IlCCCM seeks to significantly enhance the relevance of cellular 
level studies. 
tissue) often results in unnecessary noise which significantly deteriorates the quality of 
information attainable. Further, cellular level systems that utilize purified cells, allow for 
convenient analysis using both destructive and non-destructive techniques. Cells can be 
imaged using microscopy to study structure, conformation, the expression of intra- and 
extra-cellular markers, organization of organelles and other details of nuclear and 
cytoskeletal elements. Low and high- throughput techniques can be used to evaluate 
gene expression, protein expression and production of metabolites. The effect of a drug 
or therapeutic can be understood in terms of molecular signaling events that alter cell 
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phenotype and function. High-throughput cell culture using multi-well plates can be used 
to evaluate effects of variables including concentration of stimulants and time of 
exposure on cellular function. [30] The flexibility and specificity of information 
generated from cellular level systems is unparalleled and is usually an essential first step 
in any drug discovery study. However, since cell based studies use isolated cells in a 
non-physiological environment without mechanisms responsible for homeostasis, the 
relevance of these studies is limited and results need to be verified using animal and 
patient level studies. 
In-vitro studies are performed in isolation without feedback mechanisms present in the 
body. Therefore, to understand the real and long term effects of a biochemical 
compound, drug or device on an organ, a system, in-vivo evaluation is essential. Animal 
studies are used to confirm outcomes before application in the human body. Animals are 
similar in complexity to humans and the levels of organization are conserved amongst 
most species. Small animal studies are easier to perform due to cost related issues and 
availability of significant amount of information and characterization of various systems 
in animals like rats, mice, hamsters and rabbits. [24, 31] Further, technologies for 
generation of transgenic animals allows for greater flexibility with design of studies to 
evaluate targeted pathways. [32] Large animals are physiologically closer to humans and 
provide improved relevance due to greater similarities in size of organs and function of 
systems. [33-34] Large animals are particularly useful in testing implantable medical 
devices as the size of organs is comparable to humans and provides a more accurate 
representation of the actual situation. 
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Patient or clinical studies are often the last stage of evaluation for a particular drug or 
treatment. This follows pre-clinical studies accomplished using in-vitro methods and in-
vivo animal studies. Clinical trials allow assessing the safety and effectiveness of a new 
medicine or device on patients. Clinical studies are divided into phases 0, 1,2, 3, and 4. 
Phase 0 trial allows an early evaluation of the pharmacological effect of the testing drug 
in humans This is done by administrating a low dose of the test compound in a short time 
period. This phase 0 trial doesn't have atherapeutic or treatment purpose; rather, allows 
the researchers to explore the pharmacological profile of the test compound in human to 
see if it is appropriate for humans or not.[35] As a result, it helps to select the potential 
drug. The disadvantage of this phase is the poor relation between the preclinical and 
clinical effect of the testing drug. [36] Phase 1 is the first stage to test the dose effects on 
human subjects, so the appropriate dose of a certain drug on human can be found. Phase 
2 trials assess how well the drug works and continue to affIrm the safety of the drug on 
large groups. Phase 3 trials are applied on a huge group to see how effective the drug is 
for a certain type of disease. And fmally, phase 4 relates to the on-going effect of the 
drug. 
In conclusion, cell-level studies are highly specific and can be used to investigate 
molecular mediators and signaling pathways involved in disease processes. These studies 
cannot be accomplished in patients because of inherent diffIculties with isolation of cells 
and analytical techniques. Animals provide a more appropriate platform for early 
evaluation as they provide more opportunities for evaluation. To shorten the time 
between discovery and clinical validation, it is essential that cell based studies are 
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accomplished in platforms that have physiological relevance. For example: studying 
cardiac tissue under unloaded static conditions is undesirable since mechanical loading 
and fluid flow play an important role in maintaining cell structure and phenotype. 
2.2. IMPORTANT CONSIDERATIONS FOR CELL-LEVEL METHODS OF 
CAR D I ACT ISS U E 
During normal heart function, the myocardium experiences paSSIve stretching and 
pressure build-up during filling (preload) and actively generates mechanical force during 
ejection (contraction) against variable afterload. Cells in cardiac tissue therefore are 
under constant physical stimulation and rely on conversion of these cues into intracellular 
signals to control cell phenotype and muscle mass during conditions, [37] such as 
hypertrophy. Cardiac cells therefore are exposed to periodic pressure, stretch and shear 
stress. 
Physiological heart development and cardiac function rely on the response of cardiac 
tissue to mechanical stress signals during hemodynamic loading and unloading. These 
stresses manifest themselves via changes in cell structure, contractile function and gene 
expression.[31] Disruption of this well-balanced stress-sensing machinery due to various 
pathological conditions results in mechanical dysregulation, cardiac tissue remodeling 
and heart failure. To achieve physiological relevance, in-vitro models must replicate the 
complex, dynamic in-vivo interactions between cardiomyocytes and mechanical stress 
signals. Current in-vitro models do not incorporate all aspects of mechanical loading and 
therefore fail to accurately mimic the in-vivo cardiac microenvironment. 
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2.3. CURRENT STATE OF THE ART 
Despite advances in isolation and culture techniques, the current state of cardiovascular 
in-vitro models is predominantly based on glass slides or tissue culture dishes under static 
conditions.[28-29, 38] Most studies utilize isolated cells maintained in two-dimensional 
culture forming randomly oriented cell -ECM attachments. [32, 39-40] Accurate 
replication of the in-vivo environment requires consideration of several factors. First, 
tissue orientation and direction of stretch are critical determinants of cardiac cell 
signaling; therefore randomly oriented cultures cannot replicate physiological loading. 
Second, fluid flow is an important determinant as shear stress strongly influences 
endothelial and smooth muscle phenotype; hence, perfused systems are more 
representative of the in-vivo environment. Third, cyclic build-up of pressure and stretch 
during preloading are critical determinants that dictate cell structure and function. 
Fourth, synchronous contractions that enable unloading, ensures ejection of fluid that in 
turn results in relaxation of built-up pressure and stretch.[16] 
Some of the aforementioned issues have been previously addressed, albeit individually. 
Patterning of ECM proteins using techniques like micro-contact printing and lithography 
to define areas of cell attachment and directional alignment have been accomplished. [41-
43] Several groups have reported culture of cardiac cells under conditions of perfusion 
using continuous and cyclic loading to mimic in-vivo hemodynamic loading.[44-47] 
Mechanical stretch simulating hemodynamic loads are studied using technologies like 
Flexcentral Flexercell® Strain - FX-4000 Flexercell Tension Plus (TM) ,http://WWW! 
f/exce/linf.com) which consists of a flexible membrane on which cardiac cells can be 
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plated and then be subject to oscillatory deflections usmg a vacuum or pressure 
source. [48-49] Electrophysiological studies utilize systems like IonOptix Myocyte 
Systems (http://www.ionoptix.com} where cardiomyocytes grown on a glass slide are 
stimulated with an electrical impulse and analyzed for contractility via fluorescence using 
hardware and software developed by the manufacturer. However, to the best of our 
knowledge there is no system currently available that recreates all aspects of cardiac 
mechanical loading. 
2.4. PHYSIOLOGICALLY RELEVANT SYSTEMS FOR CARDIAC CELL 
CULTURE 
Various manifestations of cardiovascular diseases directly correspond to changes in 
mechanical behavior of cardiac cells. This in turn affects cellular phenotype and 
function, causing changes like hypertrophy, growth of fibrous tissue, and establishment 
of random cellular orientation. [28] For example, in hypertension, the pressure inside the 
heart exceeds the normal range due to a high resistance in vascular system and results in 
hemodynamic overloading of the heart. This higher pressure dilates the cardiomyocyte 
cells .. In the long term, this additional stretch weakens the ability to the contraction of 
heart muscle, causing heart failure. [24] In the contrast, hypotension refers to the 
condition where the pressure inside the heart is lower than the normal range. This causes 
reduced blood circulation and oxygen deprivation to the rest of the body. In response to 
this oxygen shortage, the heart rate is increases resulting in altered stretch and pressure 
profiles. 
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The frequency of the loading determines the ranges for normal and abnormal heart 
function. For example, bradycardia is a condition where the heart rate is lower than 60 
bpm [50] and tachycardia is another condition characterized by significantly higher heart 
rate (>200 bpm) in comparison to normal heart rate (~75 bpm). In response to these 
abnormal patterns, the heart either lowers or increases the systolic fraction.[51] All of 
these changes can cause the reorganization of cardiac tissue and it can lead to heart 
failure or sudden death if it persists long term.[15] 
Finally, shear stress due to fluid flow can be a significant determinant for cardiac 
endothelial and cardiac smooth muscle cells. Cardiac endothelial cells contribute to the 
internal lining of the myocardium and are directly exposed to fluid induced shear stress 
during hemodynamic loading and unloading. Changes in magnitude, frequency and 
duration of shear stress are a critical determinant of endothelial cell structure, function 
and permeability. Various clinical conditions result from changes to shear profiles seen 
by cardiac endothelial cells. 
Studying cardiovascular disease requires appropriate cellular level platforms which can 
be used to culture cells while accurately mimicking mechanical and fluidic loading 
conditions seen in-vivo. In cardiovascular disease, various conditions are associated with 
distinct mechanical loading profiles and replication of those profiles is critical to ensure 
proper understanding at the cellular and molecular levels. Mechanical loads experienced 
by cardiac cells that vary as a consequence of dysfunction include pressure, stretch and 
shear as well as the frequency and duration. 
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In conclusion, based on the discussion above, due to the complex nature of the heart and 
the importance of mechanical loads, a cellular culture model with physiological relevance 
is critical to investigate the cellular and molecular basis of cardiovascular disease. No 
device or cell culture platform available today has accomplished long term culture of 
cardiac cells in-vitro with accurate replication of mechanical loading profiles. Efforts by 
other groups thus far have succeeded in replicating isolated mechanical loads. There is 
still a need for platforms where the culture conditions can be dynamically varied to not 
only replicate normal loading conditions, but also abnormal loading conditions. These 
platforms are necessary to study the molecular pathophysiology of cardiovascular 
diseases and in the discovery of drugs, treatment options and cardiac cell regeneration 
strategies. 
22 
CHAPTER 111- DESIGN AND FABRICATION OF THE JlCCCM 
3.1. MECHANICAL LOADS IN THE HEART 
The magnitude and duration of stretch and contractions in cardiac tissue depend on the 
preload and afterload conditions. In the heart, specifically in the left ventricle, preload 
refers to the condition when the filling of blood inside the ventricle causes the stretch of 
the wall during the diastolic phase. Afterload refers to the resistance in the system that 
needs to be overcome to pump blood out of the ventricle via opening of the aortic 
valve.[lS] This directly affects the contractile force that needs to be generated by 
cardiomyocytes. Overcoming this pressure opens the aortic valve for ejecting the blood 
into the aorta. 
Preload increases when blood filling the chamber during diastole increases, which creates 
greater systolic pressure for the subsequent contractions. This systolic pressure continues 
to increase until its maximum systolic pressure is reached at the optimal preload. At a 
constant preload, through the ventricular contraction, higher systolic pressure can be 
obtained by raising the afterload condition such as increasing the aorta pressure.[lS] 
However, if the afterload keeps increasing, the ventricle cannot create enough force to 
open the aortic valve to push the blood out of the heart. At this point, the systolic phase 
is totally isovolumetric. Preload and afterload, as a result, depend on the vascular system 
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and the behavior of the heart including peripheral resistance, the frequency of the heart's 
contraction, and change of the stroke volume.[15] 
3.2. IN-VITROTECHNIQUES FOR MECHANICAL STIMULATION OF CELLS 
There are different ways to mechanically stimulate cells in in-vitro culture to replicate 




Cells in different tissue experience compressive loads due to pressure buildup. Cardiac 
and vascular tissue are examples of tissue where cells within the tissue are constantly 
under compressive loading. Replicating this condition in-vitro can be accomplished 
using different techniques such as application gas pressure (hydrostatic compression) 
directly to the culture system or through the fluid induced loading of the system 
(pressure loading).[17] These techniques cause direct application of pressure to cells in 
culture mimicking conditions seen in-vivo. 
Another commonly seen loading condition in cardiac and vascular tissue is stretch. The 
most common approach to stretch the cells in culture is by growing the cell on a flexible 
surface and applying stretch on the surface where the cells are attached. The stretch can 
be either uniaxial or biaxial. [17] With the uniaxial stretch, the surface is either 
rectangular or square and is stretched in one direction either longitudinally to both ends 
or is bentlflexed in a four-point bending. With the biaxial stretch, the membrane is 
24 
circular and the edge of the membrane is fixed. The applied pressure deforms the 
membrane in both the radial and circumferential directions.[17, 52] However, the strain 
depends heavily on the location on the membrane, causing the cells on different locations 
to stretch differently. For example, cells seeded at the center will stretch more than those 
at the edges. As the result, it is extremely complicated to analyze the data and to interpret 
the cells behavior. To produce equi-biaxial strain, the membrane has to slide non-
frictionally on a stable plane. On this plane, the stress distribution on the area of 
membrane where is supported by the plane is symmetrical, creating an isotropic and 
spatially constant strain.[17, 52-54] 
Finally cells in different tissue experience shear stress as a consequence of fluid flow.[17] 
Shear stress is a key mediator of cells phenotype and controls alignment and 
establishment of cell-cell contacts important in the formation of tight junctions which are 
extremely important in ensuring low permeability in vasculature. The velocity as well as 
the pattern of the flow, laminar versus turbulent flow for example, can create different 
shear stress on the cells. Also, viscosity of the fluid is another factor that can increase or 
decrease shear stress on the cells.[17] 
In cardiac and vascular tissue, all three of these loads are experienced simultaneously. 
Additionally changes in one or more of these loads have a cascading effect on the entire 
system. Therefore in-vitro models of cardiac tissue need to accurately mimic the 
combined effects of pressure, stretch and shear in a pulsatile fashion. 
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3.3. COM PO N EN TS 0 F THE ~ C C C M 
The /lCCCM was designed to mimic the functioning of the left ventricle in the heart. 
This system consists of a peristaltic pump, cell culture chamber, pulsatile actuated 
collapsible valve and a tunable resistance element in series along with accessories that 
include tubing, an oil chamber, a pressure generator, and a digital manometer. 
The /lCCCM, fabricated using standard soft-lithography techniques consists of a small 
(~lcm diameter) cell culture chamber on a thin silicone membrane. Continuous 
circulation of culture medium is maintained using a peristaltic pump. Downstream of the 
chamber is a collapsible valve actuated in a pulsatile fashion using a pressure generator. 
Closure of this collapsible valve leads to pressure build up in the chamber which in turn 
also leads to stretching of the thin membrane on which cells are cultured mimicking 
diastolic preloading in the heart. To ensure uniformity, a post is placed beneath the thin 
membrane such that during stretch, the portion of the membrane on which cells are 
cultured experiences uniform strain and the edges experience larger non-uniform strain 
(Fig. 3.1). A tensile ring is used to ensure that the cells do not grow on the edges of the 
membrane, but on the thin membrane area that rests on the post but. Lubricating oil is 
filled in the chamber beneath the cell culture area which contains the post such that there 
is friction-free sliding of the membrane on the post. Further to influence outflow 
resistance, a tunable homeostasis valve is placed downstream of the collapsible valve to 
mimic afterload. This system is programmable and can accommodate a wide range and 
different combinations of operating parameters. Fluid transport and shear stress can be 
controlled by setting the flow rates of the pump. Pressure buildup and strain can be 
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controlled via a combination of factors including fluid flow rate and operation of both 
valves. Strain is also a function of the thickness of the membrane on which cells are 
cultured. 
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Fig u re 3.1. Setup design for equi-baxial strain. A significant deformation at the edges of the 
membrane occurs when the pressure is applied, but the area of the membrane rested on the post 
has the same radial and circumferential strain. 
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The J..lCCCM is unique in the sense that it mimics the native heart where changes in one 
or more variables have a cascading effect the entire system. For example, increasing the 
outflow resistance by manipulating the hemostatic valve indicates a system with high 
afterload. This in turn results in an increase in base pressure and baseline strain within 
the cell culture area mimicking conditions experienced during aortic stenosis or 
hypertension. 
3.4. POLYDIMETHYL SILOXANE AS A MATERIAL FOR MECHANICAL 
STIMULATION 
Polydimethyl siloxane (PDMS) is a pre-polymer: Sylgard 184 Silicon elastomer base and 
Sylgard@184 silicone elastomer curing agent, manufactured by Dow Corning Corporation 
(Midland, MI). The PDMS rigidity can be controlled by the concentration of its cross-
linker agent, the temperature, and the time of baking. The Young's modulus for PDMS is 
-360-870 KPa with the density of9.7 x 10_2 kg/m3. lts fracture strength and poisson ratio 
are 2.24MPa and 0.49 respectively. [55] 
PDMS is a substrate widely used for cell behavior studies because it is biocompatible 
and gas permeable. This silicone is also physically, chemically stable. PDMS also has a 
high flexibility and compressibility which is a good candidate for a thin stretchable 
membrane in J..lCCCM. PDMS material is also transparent; it is easy to monitor the fluid 
flow, to determine the functional integrity of fluidic circuits, or to check the cell behavior 
and structures under a microscope. In addition, PDMS is easy to mold or bond either to 
itself or to other materials including a glass slide; and is inexpensive. However, PDMS is 
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a highly hydrophobic po lymer (contact angle is 90°-120°). [55] For the cells to attach and 
grow on it, PDMS membrane needs to be coated with ECM, such as fibronectin, laminin, 
or collagen. 
3.5. DESIGN AND FABRICATION OF DIFFERENT COMPONENTS OF THE 
~CCCM 
3.5.1. Assembly for Housing the Cell Culture Platform 
The assembly for housing the cell culture platform was fabricated in the Rapid 
Prototyping Facility at the University of Louisville using Computer Numerical Control 
(CNC) Milling Machine. The designs were laid out using Solidworks 3D layout software 
prior to machining the assembly using CNC milling. Acrylic was used for construction. 
This platform consists of identical top and bottom rectangular pieces (l0.16 cm x 15.24 
cm x 1.27 cm). The top piece has two half-circular channels (1 = 2.54 cm, d = 0.38 cm) 
and two holes (d = 0.38 cm) at the outer ends of these two channels. (Fig. 3.2) The 
distance between two inner ends of these channels is 0.90 cm. The bottom part of the 
platform has two centric rectangular holes (7.62 cm x 5.08 cm x 0.64 cm and 5.08 cm x 
2.54 cm x 0.64 cm). Finally, the platforms contain holes drilled all the way through at 
the comers for insertion of the screws. 
3.5.2. Thin PDMS membrane 
PDMS membranes were prepared by mlxmg 9.0 g of Silicon elastomeric base 
(Sylgard®184, Dow Conrning, Midland, MI) with 1.0 g curing agent for 1 minute. 
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Figure 3.2. Schematic representation of the top and bottom pieces of the platform for housing the 
cell culture chamber. (A): the top part of the platform with inlet and outlet accesses and (8): the 
bottom part of the platform with two rectangular holes at the center. 
Vacuum was then applied to the mixture to remove air bubbles created during the mixing. 
After 15 minutes, the remaining air bubbles on the surface were removed with a gentle 
stream of compressed air. Then, this mixture was used for thin membrane fabrication. 
Approximately 5.0 g of the degassed PDMS mixture was placed on a non-oxidized 
silicon wafer (0.525 mm thick, 100mm diameter, Silicon Valley Microelectronics, Inc. 
Santa Clara, CA) and spun at 400 rpm for 30 seconds on a Headway Spinner (Brewer 
Science, Inc., Rolla, MO) (See Appendix E for programming the spinner). The PDMS 
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coated wafer was then baked at 115 °C on a Standard Model 1100 Hotplate (Brewer 
Science, Inc. , Rolla, MO) for 15 minutes. Once the PDMS was cured, the wafer was 
removed from the hotplate and cooled to room temperature. The membrane on the 
silicon wafer was then used for bonding to the cell chamber. The membrane thickness is 
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Figure 3.3. Membrane thickness versus spinning speed. The membrane thickness as a function 
of spin speed can be estimated using the equation y= , 130728 X-I05 
3.5.3. Cell culture chamber and medium reservoir 
To make a cell culture chamber with a thickness of 0.35 cm, a 65 g of the degassed 
PDMS mixture (10:1 ratio, as in the session 3.2 above) was molded evenly in a 15 cm 
diameter Petri dish and cured completely at 75 °C in an oven (Fisher Isotemp, Florence, 
KY) for at least 3 h. Then, the molded PDMS was removed from the Petri dish and a 
31 
rectangular piece ofPDMS (7.5 cm x 3.0 cm x 0.35 cm) was cut. A hole (d= 1.4 cm) was 
punched at the center of this PDMS rectangular piece using a cork borer #7 (CB #7) 
(Fig. 3.4). A horizontal channel was created from the center to the outside edge of the 
PDMS rectangular piece with the use of an 18 gauge (180) blunt syringe needle 
(SmallParts, NEI81PL-C). The PDMS piece was then cleaned with the clear adhesive 
tape to remove the dust particles from the surface. 
Rectangular piece 




Create a channell . 
' -Blunt needle 
Cell chamber 
wit hout thin membrane 
"6> ~ 1 Punch hole 
Tens-ile ring 
Fig u re 3.4. Schematic representation of fabrication steps involved in construction of the cell 
chamber, the tensile ring, and the medium reservoir. 
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The PDMS piece and the thin PDMS layer were bonded irreversibly following exposure 
to 02 plasma in a reactive ion etcher (RIE March Instruments) with 10% oxygen plasma, 
100 mmTorr, and 100 mmHg. After a 30 second exposure, the pieces were aligned and 
bonded and subject to heating for a period of 10 minutes at 115°C on the 1100 hotplate to 
enhance the quality of bonding. Finally, the PDMS rectangular piece with the thin 
membrane at the bottom was gently peeled off from the silicon wafer to form a cell 
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Fig u re 3.5. Procedure for fabrication of cell culture chamber 
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PDMSpiece 
To make a tensile ring (0.8 cm inner diameter, ID, and 1.4 cm outer diameter, OD), the 
1.4 cm diameter piece removed from the center of the rectangular piece made above was 
punched again at the center with a CB #4 (Fig. 3.4). To provide enough medium for the 
cell culture, a medium reservoir was also made of PDMS. A hollow PDMS rectangular 
piece (4.0 cm x 3.0 cm outside and 3.0 cm x 2.0 cm inside edges) was cut from the 
PDMS in a Petri dish (Fig.3.4). Clear adhesive tape was used to remove the dust 
particles from the reservoir and the tensile ring. 
3.5.4. Oil chamber 
To make the oil chamber, a rectangular PDMS (7.0 cm x 2.5 cm x 0.35 cm) was cut and a 
hole (d= 1.7 cm) was punched at the center with the use of a CB #9. An 18G blunt 
syringe needle was used to create two horizontal channels on either side and two 16G 
blunt syringe needles were inserted into these channels. This rectangular PDMS piece 
with the needles was placed on an acrylic sheet (7.0 cm x 2.5 cm x 0.25 cm) (Fig.3.6). 
PDMS was used to glue the holed PDMS rectangular piece with the acrylic sheet. An 
acrylic flat surface post (d= 0.85 cm, h =0.35 cm) was placed at the center of the hole of 
the PDMS rectangular piece and glued with PDMS. The pieces were placed in an 
incubator at 75°C for 10 min. 
3.5.5. Collapsible valve 
The collapsible valve was assembled by inserting two ends of a 6 cm long Latex Penrose 
tube (ID = 5 mm, OD = 5.5 mm, ARGYLE™ Penrose Tubing) into 2 Teflon tube (OD= 
0.65 cm, 1=10 cm) (Fig. 3.7.). Then, this setup was inserted inside ofa Poly Allo/M T-
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connector e;,. x % x 12 inches, ApolloPEX). The ends of the T -connector were sealed 
tightly with PDMS rings (3 for each end, h = 0.35 cm, ID = 0.7 cm, OD = 1.95 cm). 
These PDMS rings ensured that no air leaked out of the T -connector when air was 




Figure 3.6. Fabrication and assembly of the oil chamber. 
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end 
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T-eonnector 
Insert POMS 
rings to the right 
end 
Figure 3.7. Assembly of the collapsible valve. (A) Steps to assembly the collapsible valve and 
(B) Assembled collapsible valve. 
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3.6. ASSE M B L Y 0 F THE ~ C C C M 
To establish supporting base for the oil chamber, an acrylic sheet (7.0 cm x 2.5 cm x 0.25 
cm) was placed in the rectangular hole on the bottom piece of the platform followed by 
the oil chamber (Fig. 3.8). Then, the cell culture chamber, with 18G needle inserted, was 
aligned on the top of the oil chamber in such a way that the post was centrically 
underneath of the thin PDMS membrane. The top piece of the platform was laid on the 
top of the cell chamber. The platforms were tightened with four screws. Finally, low 
viscosity oil was injected into the oil chamber through needles. 
Place acrylic sheet 
on the 
Bottom platform 
Place oil chamber 
on the acrylic sheet 
Align cell chamber I 
on top of oil chamber -!-
Place the top platform I 
on top of cell chamber '" 
screws o anometer 
Figure 3.8. Assembly of the cell culture and oil chambers between the platform. 
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A 3-stop Pharmed BPT tube (1.3 mm ID, Cole-Parmer, Vernon Hills, IL) was connected 
from a 50 mL medium container to the inlet of the device via a peristaltic pump (lsmatex, 
ISM 596D, Vancourver, MA). The collapsible valve was connected from the outlet of 
the device to the medium container. The tunable valve was placed downstream of the 
collapsible valve (Fig.3.9). Finally, the pressure sensor was connected to the needle 
which was connected to the cell chamber. A pulsatile pressure generator was connected 
to the bottom T of the collapsible valve. 
Figure 3.9. Assembled j.lCCCM for cell culture experiment. In this picture, two cell culture 
system were set up: the system on the left side was for flow only without valves (control). The 
other system on the right side has a tunable valve and a collapsible valve. Both systems have a 
circulating fluid network. 
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3.7. OPERATION OF THE ~CCCM 
Once assembled as in Fig. 3.9, the pump was started with an initial flow rate of 3.0 
mLimin for about 30 minutes to enable seeded cells to gradually adapt device conditions. 
After 30 minutes, the flowrate was gradually increased until it reached 8.6 mL/min and 
the system was run for extra 15 more minutes. Then, the pressure in the pneumatic 
pressure generator source was gradually increased and tunable valve adjusted until the 
pressure reached the desirable values. The pressure was increased about 15mmHg every 
15 minutes (refer to Appendix E for further detail information about the operation of 
IlCCCM). Variable parameters such as the frequency of the membrane stretching as well 
as the percentage of systolic phase per one cycle were determined based on the 
requirement of each experiment. The frequency of the stretching was controlled through 
the % systolic and the frequency control on the pressure generator source. The pressure 
inside the cell chamber was varied by the corroboration between the pressure applied on 
the collapsible valve and the adjustment ofthe tunable valve. The stretching level of the 
membrane was determined by the thickness of the membrane and the pressure applied on 
the membrane. And the shear stress on the cells is controlled by the velocity of the fluid 
loading and the dimension of the cell culture chamber. For proof of concept studies, peak 
pressures of 120 mm ofHg, strain of20% and a frequency of80 bpm with 50% systolic 
to diastolic were used. 
3.B. CONCLUSION 
The IlCCCM were created based on the mechanical loading conditions observed in the 
heart and a combination of techniques for mechanical stimulation on cells in- vitro cells. 
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When working with different types of cardiac cells, it is important to ensure that the type 
of mechanical loads delivered such as the stress, stretching, frequency of stretching, and 
the shear stress can be dynamically controlled. The )lCCCM allows for dynamic studies, 
accomplished via direct manipulation of flow rate, valve operation, membrane thickness 
and the height of the cell culture chamber. This system is capable of accurately 
mimicking preload and afterload experienced in the healthy and failing heart. 
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CHAPTER IV-CHARACTERIZATION OF PRESSURE, STRETCH, 
AND SHEAR STRESS 
4.1. IN T ROD U C I TO N 
Application of the flCCCM for in-vitro studies of CVDs requires establishment of the 
ability of the system to simulate mechanical loading conditions associated with 
cardiovascular diseases observed in-vivo. These include the differences in pressure inside 
the chamber, strain that the cells experienced during the stretching, and the shear stress 
that the cells are exposed, specifically for cardiac endothelial cells. Pressure inside a left 
ventricle is an important factor that determines the contractility and the relaxation of the 
cells; therefore, different conditions associated with normal, high and low pressure such 
as heart failure, hypertension and hypotension were simulated using this system. In 
addition, the frequency of the heart beat was also varied to mimic conditions such as 
bradycardia and tachycardia. The percentage of the strain often varies in response to 
changes in preload and afterload seen in various manifestations of CVD. Other 
parameters associated with cardiac tissue like stretch and shear stress have also been 
accurately replicated. This chapter details all experiments performed to characterize the 
system. 
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4.2. PRESSURE CHARACTERIZATION 
4.2.1. Setu p of the ~ C C C M system 
The device was assembled and the pressure build-up within the chamber was 
characterized for the following clinically relevant experimental conditions - (1) normal, 
(2) heart failure, (3) hypertension, (4) hypotension, (5) tachycardia, and (6) bradycardia. 
To accomplish pressure monitoring within the chamber, a small hole was punched using 
a 24 gauge syringe needle. An 18 gauge needle was then inserted into the hole to form a 
tight seal and attached to a hemostatic valve using luer connectors. A high-fidelity 
pressure catheter (Millar Instruments, Boston, MA) was inserted through a hemostatic 
valve and syringe needle such that the pressure sensing element resided in the center of 
the chamber. The chamber pressure data were signal conditioned and analog-to-digitally 
converted at a sampling rate of 400 Hz in 30-second recording epochs and stored for 
digital analysis with a clinically approved Good Laboratory Practice - compliant data 
acquisition system. The transducers were pre- and post-calibrated against known 
standards to ensure measurement accuracy. The chamber pressure waveforms were 
analyzed by using a Hemodynamic Evaluation and Assessment Research Tool program 
developed in Matlab (MathWorks, Natick, Mass). 
4.2.2. Results 
For various simulated conditions in the setup shown in Figure 4.1, the pressures inside 
the chamber were monitored and recorded. For a rate of 75 bpm, and a 40% systolic 
fraction, the ~CCCM produced a peak pressure of 123 mmHg and an end diastolic 
pressure of 10 mmHg. The simulation of heart failure showed a lower peak pressure of 
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95 rrunHg and a higher end diastolic pressure of 27 rrunHg. Both hyper- and 
hypotension test simulation produced normal end diastolic pressures (8-10 rrunHg). 




Fig u re 4.1. Setup for pressure characterization. (A) The whole setup; (B) Pressure catheter 
inserted into the cell chamber. 
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(92 nunHg) was achieved for hypertension. Tachycardia simulations resulted in a 
significantly higher beat rate (>200 bpm), lower end diastolic value (3 mmHg), and a 
higher systolic fraction (55%) compared to normal test condition. Simulated bradycardia 
showed a lower beat rate (46 bpm), and slightly lower systolic fraction (38%) compared 
to normal test condition. The values and waveforms obtained with the use of the 
~CCCM (Table 4.1 and Fig. 4.2) closely match those found in the literature for human 
left ventricular. 
4.2.3. Discussion 
As shown in Figure. 4.2, the peak pressures of the waveform obtained in the ~CCCM 
system could be considered as end systolic pressure and the lowest peak as end diastolic 
pressure. The patterns of these waveforms could be explained through the concept of 
heart loading mentioned in the session lA. When the collapsible valve was closed, fluid 
accumulated inside the chamber in similar fashion to preloading in the heart. The 
pressure buildup in the closed chamber resulted in stretching of the membrane. This 
mimics the isovolumetric contraction of the heart. Once the membrane began to stretch, 
the volume of the chamber increased and the pressure inside the chamber also increased 
but slowly. When the collapsible valve was opened, fluid inside the chamber was 
released, causing the pressure to decrease. Initially, the reduction of the pressure was not 
significant due to energy recovery of the membrane and the fluidic resistance caused by 
a tunable valve. However, once the membrane was fully restored, isovolumetric 
relaxation occurred and the pressure decreased significantly, back to the initial pressure. 
This process mimics the diastolic phase and the afterload condition in the heart. 
44 
Tab Ie 4.1. Different parameters corresponding to mechanical loading of the left ventricle were 
replicated using the flCCCM. These parameters include heart rate, systolic fraction, end systolic 
pressure, and end diastolic pressure. L VP (left ventricle pressure). 
LVP end 
Systolic L VP systolic 
Heart Rate diastolic 




Normal 75 40 123 10 
Heart Failu re 75 40 95 27 
Hype rtension 75 40 183 8 
Hypotension 75 40 92 11 
Tachycardia 200 55 112 3 
Bradycardia 46 38 115 10 
In HF, the end-systolic pressure is lower but the end-diastolic pressure is higher than 
normal heart condition. This condition was reproduced by the J.lCCCM. This was 
obtained by reducing the pressure of the pressure generator source (the collapsible valve 
not fully collapsed) and increasing the fluid resistance through the tunable valve. 
Cardiac hypertrophy and hypotrophy conditions occur when the pressure inside the heart 
is high or low respectively but the contractile function of the cells is still normal to eject 
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Figure 4.2. Pressure waveforms for varIOUS physiologic conditions replicated using the 
~CCCM. These conditions include both normal and dysfunctional myocardium, such as, heart 
failure, hypertension, hypotension, bradycardia, and tarchycardia. These results confirmed that 
the ~CCCM enabled to recreate various clinically relevant physiologic conditions. 
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(hypertension) or low (hypotension) while the end diastolic pressure is the same as in 
normal heart condition. These conditions were also recreated under the ~CCCM system 
by either increasing or decreasing the pressure in the pressure generator in order to 
control the closure level of the collapsible valve and by adjusting the tunable valve. 
Lower or faster frequency of the heart beating can create health problem. Tachycardia 
condition occurs when the heart beat is between 150 bpm to 200 bpm. [56]. In contrast, 
the heart beat in bradycardia condition is lower than 60bpm.[50] To eject all the blood 
out of the heart, the systolic fraction under tachycardia condition needs to be increased, 
but this fraction needs to be decreased in bradycardia. In addition to the beat frequency, 
both the end-systolic pressure and end-diastolic pressure must be the same as in normal 
condition. These conditions were obtained in the ~CCCM by increasing or decreasing 
the systolic fraction per cycle and the frequency of the heart beat in the pressure 
generator. 
In conclusion, the manipulation of different elements of the ~CCCM enabled recreation 
of various clinically relevant physiologic conditions of the heart. 
4.3. STRAIN CHARACTERIZATION 
4.3.1. Setu p of the ~ C C C M system 
Strain developed on the thin membrane was experimentally evaluated. Before 
assembling the device, the post surface and the outside bottom of the thin membrane 
were marked with tinny black dots by a fine marker (Fig.4.3A). Then, the cell chamber 
and the oil chamber were assembled as explained previously (sessions 3.5 & 3.6). For 
47 
the strain characterization, a 30 mL syringe filled with water and a hemostatic valve were 
connected to the inlet and outlet ofthe cell chamber, respectively. The syringe was used 
to apply different pressures to the cell chamber via fluid loading (FigA.3B). To measure 
the pressure inside the chamber, a digital manometer dV -2 was used. To track the 
position and displacement of the dots, a CCD camera coupled to fluorescence microscope 
(Nikon Eclipse TE2000-U) was used. 
Figure 4.3. Setup for strain characterization. (A) Membrane and the post marked with black 
dots, and (B) Entire setup for the strain characterization. 
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4.3.2. 0 pe ration of the system 
Water was injected slowly with the use of the syringe into the cell chamber. After the 
chamber was totally filled with water, the air bubbles trapped in the cell chamber were 
removed. Then, the hemostatic valve connected to the outlet was closed. To increase or 
decrease the pressure inside the chamber, the syringe was gently pushed or pulled. The 
baseline pressure was set up as 0.0 mmHg. 
Under the microscope, the dots on the post were considered as the reference points while 
the dots on the membrane were tracked with a CCD camera while pressure was applied. 
To measure the strain, pictures of the membrane were taken before and after the 
application of the pressure. Then, the distance between the reference point on the post 
and a dot on the membrane were measured before (Lo) and after (Lf) the application of 
the pressure. The data was then analyzed using Microsoft Excel. 
4.3.3. Results 
Five different membrane thicknesses were used (329 )lm, 192 )lIll, l35 )lm, 93 )lm, and 
35 )lm) and five different pressure values (60 mmHg, 80 mmHg, 100 mmHg, 120 mmHg, 
and 140 mmHg) were applied to each membrane. At least five different changes of 
relative positions were measured for each experiment. The % strain values and standard 
deviation for different pressures and membranes were calculated. 
%Strain (Lt Lo) 100 
Lo 
where, Lo is the length between two dots at 0.0 mmHg and Lf is the length after pressure 
was applied. 
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The pressure and the percentage strain values as a function of the pressure applied for 
each membrane are shown in Table 4.2 and Figure. 4.4. As can be seen from Figure 4.4, 
the strain values correlate linearly with the pressure applied on the membrane. Moreover, 
the percentage of the strain increases when the thickness of the membrane decreases. By 
varying the thickness of the membrane and the pressure applied on the membrane, the 
percentage strain obtained could be as low as 4.15% and as high as 60.2%. The % strain 
of the cells in the heart is anywhere between 5% to 25%.[57], [58] 
Table 4.2. % strain determined for various pressures on membranes with different thicknesses. 
Pressure/thickness i 329 pm 
I 
The error bars in the Fig. 4.4 are large due to two main reasons. First, the pressure sensor 
has a low frequency that is not sensitive to the precise pressure changes in the cell culture 
chamber. Second, the post underneath of the membrane was not aligned exactly at the 





















F igu re 4.4. % strain as a function of pressure for different membrane thicknesses. 
4.3.4. Discussion 
In addition to the pressure stimulation, stretch levels in cardiac cells playa critical role 
ensuring cell phenotype and function. In the JlCCCM system, cardiac cells were attached 
and grown on the thin PDMS membrane and the % strain of the PDMS membrane 
represents the stretch level ofthe cells growing on it. The result showed that the % strain 
of the membrane was determined by the thickness of the membrane and the loading 
pressure. The % strain was directly proportional to the pressure but inversely 
proportional to the thickness of the membrane. 
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In conclusion, base on the % strain found for the PDMS membranes and the % strain that 
the cells are exposed in the heart, these membranes could replicate in vivo stretch 
experienced in the heart. 
4.4. SHEAR STRESS MODELING 
4.4.1. Method 
Finite element software ANSYS Academic Teaching Advanced 12.0, FLOTRON 
module, was used to generate the wall shears stress as a function of channel height and 
flow rate. The system modeled using a 2D simulation and environment was verified for 
steady incompressible flows. For the simulation, it was assumed that the participating 
fluid has the same physical properties of water, including the density (p = 1000 kg m-3) 
and dynamic viscosity (11 = 10 Pa s). The inlet fluid flow rates of 8.6 mL fmin, was 
applied while the outlet was set as zero pressure. It was also assumed no-slip boundary 
conditions for the channel and groove walls. The fluid domain was meshed using 2D 
quadrilateral element, FLUID141, to model steady state fluid. A segregated sequential 
solver algorithm was used; that is, the matrix system derived from the finite element 
discretization of the governing equation for each degree of freedom was solved 
separately. The mesh was refined through mesh sensitivity analyses: at each simulation, 
the elements showing high velocity gradients were refined, until reaching convergence of 
sensitive measures of the predicted quantities. 
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4.4.2. Results 
Four wells with different depth (0.25, 2.00, 4.00, and 8.00 mm) were used; and a velocity 
of ~ 0.024 mls at the inlet of the wells was applied in all the experiments. The shear 
stress ('r) was determined using the equation [59] 
du 
dy 
where't is the shear stress(dynes/cm2), ~ is viscosity coefficient (kg/(m.s)), u is the fluid 
velocity (mls), and y is the thickness of the well (m). The viscosity (~) of water at latm 
and 20°C is 1.0 X 10_3 kg /(m.s).[59] 
4.4.3. Discussion 
The shear stress simulation (Fig. 4.5) showed that for the wells with depth of 2.00, 4.00, 
and 8.00 mm, the shear stress was nearly 0.0 dynes/cm2 at the bottom of the well to 
approximately 200 ~m above of it. However, for the well with a 0.25 mm depth, shear 
stress was significantly high (~ 10 dynes/cm2) at 200 ~m from the wall and below, in the 
region where cells were cultured within the device. An additional variable which has a 
major effect on shear stress but was not evaluated due to cascading effects on pressure 
and stretch is the inlet fluid flow velocity. This characterization affirmed that the 
~CCCM can monitor the shear stress based on the height of the cell chamber and the 
velocity of the fluid flow. 
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(a) Well Depth: 0.25 mm 
(b) Well Depth: 2 mm 
(c) VVeIl Depth:. 4 mm 
(d) Well Depth: 8 mm 
taL SOLOTIOII 
I n ... 
0. .007 U .ClS' '7 .023' .4).316 1 
.003957 .01187 .01 113 .Ol'6 7 .03561 
flow velocity (m/s) 
Figure 4.5. Shear stress simulation for the cell culture chamber of the f,lCCCM. This 
shear stress was simulated with an inlet flow velocity of 0.024 m/s and various well 
depths. Note that the shear stress is negligible in the region where cells are cultured for 
all well depths except the 0.25 mm deep welL 
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4.5. CONCLUSION 
Overall, the characterization of pressure, strain, and shear stress affirmed strongly that the 
/lCCCM can be used to replicate the in-vivo heart function. This replication can be 
accomplished through a combination of different variables such as membrane thickness, 
the height of the cell chamber and adjustment oftunable components including the 
collapsible valve, tunable valve, the peristaltic pump, and the pressure generator. 
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CHAPTER V- CELL CULTURE WITHIN THE flCCCM 
5.1. C ELL C U L T U R E WITH IN THE ~ C C C M 
Cardiac tissue is 3-dimensional and consists of cells within an organized extracellular 
matrix. Cells cultured in-vitro are often grown in mono layers on tissue culture dishes or 
flasks. To demonstrate proof of concept of the ability of the /lCCCM to establish cardiac 
cell culture in-vitro, H9c2 cells were cultured under normal mechanical loading 
conditions. Their ability to survive mechanical loading, phenotype, structure and 
function were evaluated using microscopy. Preliminary results indicate successful cell 
culture, establishment of an in-vivo like phenotype, alignment of f-actin stress fibers and 
increased activity representative of cardiomyocyte contractile function. 
5.2. H9c2 CELL LINE 
H9c2 is an immortalized cell line derived from embryonic BDIX rat cardiac tissue and 
has structural characteristics of a striated muscle cells.[60] An advantage of using this 
type of cell line as the first step for system validation is the fact that despite their 
unlimited lifespan, these cells still maintain their morphology, metabolic activities and 
gene expression. Therefore, the experiments can be repeated easily, and the results 
obtained are reproducible and reliable. 
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The characteristics of the H9c2 cells under mechanical stimulus are similar to those of 
striated muscle cells,[60], which are composed of sarcomeres as contractile units. When 
cultured in-vitro, H9c2 cells can attain different shapes depending on conditions for 
attachment and growth (Fig. 5.1). H9c2 can attain polygonal or flat spindle shapes, when 
they directly attached on the bottom of the culture dishes. Spindle shape cells usually 
arrange in parallel to one another. However, when the cells were on top of each other, 
they appear as spherical and angular shapes. In the quiescent culture condition, most 
cells are mono nucleated and most nuclei appear spherical and contain to several 
nucleoli. [60] 
Fig u re 5.1. Different shapes of the H9c2 under the static condition: (A) An angular cell 
(B) Polygonal cells, (C) A spherical cell (D) A single spherical cell (arrow) on a densely 
grown layer. 
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5.3. eEL Leu L T U R E 
H9c2 embryonic cardiomyogenic cell line was used for all the experiments. The cells 
were maintained in culture using high glucose Dulbeco's Modified Eagles' Medium 
(Cellgro DMEM, 4.5 g IL glucose, Cat# 1O-0130V, Herdon, VA) supplemented with 
10% fetal bovin serum (Hyclone FBS, Cat # SV30014-03,Logan, UT) and 1% penicillin-
streptomycin-glutamine (Cellgro, Cat # 30-009-CI, Herndon, VA). Detailed protocols 
and recipes are in the Appendix C and D. 
5.3.1. Preparation of the cell chamber 
For each experiment, three sets of cell chambers were needed: static culture condition, 
constant perfusion, and pulsatile stretch. The static and continuous flow sets were used 
as controls. 
Two days pnor to seeding, the thin PDMS membrane, tensile rings and medium 
reservoirs were sterilized with 70% isopropanol. The cell culture chambers with PDMS 
membrane (Session 3.5.3) was treated with 10% oxygen plasma for 1 min and then a 
sterilized 18G needle was inserted into the channel of the chamber (Fig 5.2). To 
accomplish patterning of cells, a tensile ring was then placed inside the well of the cell 
chamber to limit the cells to grow on a circular area of 0.8 em diameter. A medium 
reservoir (Session 3.5.3) was added on the top of the chamber. The assembled cell 
culture chamber was filled with 100 ~L of ECM solution (Appendix CA). For 
sterilization, UV light was applied to the chambers for 4 min. Chambers with were 
incubated for 24 h at 37°C or for 3 days at 4°C. 
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Insert needle 
Insert tensile ring 
Add reservoir 1 
Cell chamber 
with membran e 
Tensile ring 
reservoir 
Figu re 5.2. Assembly of the cell culture chamber. Insertion of the needle, addition of 
tensile ring, and medium reservoir. 
5.3.2. Cells culture in the chamber 
H9c2 cells in a cell culture flask were trypsinized, centrifuged and re-suspended in a 
fresh H9c2 cell culture medium. Before seeding the cells in the device, the ECM solution 
in the chamber was removed and the chamber was washed with warmed medium. Then, 
a 100 ~L of resuspended cell solution (2.5 x 105 cells ImL) were added into the center of 
the well. The cells were allowed to attach and spread out for 4 hat 37 °C. After 4 h, 
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approximately 1.0 to 1.5 mL warm fresh medium was added and the cells were incubated 
at 37°C for 48 h. Cell culture medium was changed every day. 
5.3.3. Assembly of the ~ C C eM for cell cultu re 
To avoid contamination, the assembly of the IlCCCM was performed under the cell 
culture hood. After 48 h, cells in the chambers were 100% confluent. The medium 
reservoir and the tensile ring were gently removed and the outside bottom of the 
membrane where the cells were seeded was marked with tinny black dots by a fine 
maker. One chamber with the cells was used to culture the cells in static condition while 
the others two were used to culture the cells under constant perfusion (only flow) or 
under perfusion and pulsatile stretch (flow and pressure). 
The cell culture devices were assembled as explained in Session 3.4. For constant 
perfusion, the collapsible valve was not used. Instead, only a Pharmed BPT tubing (1.3 
mm ID, Cole-Parmer, Vernon Hills, IL) was connected from the outlet of the device 
back to the 50 mL medium container (Fig. 3.8). To check for leakage, the IlCCCM was 
tested under the hood and then placed in the cell culture incubator to perform the 
experiments. 
5.3.4. Operation of the ~CCCM with cultured cells 
Initially, cells were exposed to a flow rate of2.0 mL Imin for 15 minutes. Then, the flow 
rate was gradually increased to reach 8.6 mL Imin. After 15 minutes, the pulsatile 
pressure was applied to the cell chamber and was increased slowly, from 15 mmHg 10 
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mmHg to 80 mmHg/O mmHg, with 50% systolic and 80 bpm setup using the pressure 
generator. The pressure inside the chamber was monitored by a digital manometer dV-2 
connected to the cell chamber. 
After 24 h, the system was stopped gradually. First, the pressure was reduced slowly, 
then, followed by the reduction of the flow rate. The system was removed from the 
incubator and its parts were disassembled carefully. For immunofluorescence 
experiments, cells were fixed with warm 4% PF A immediately after the platforms were 
removed. Cells were immunostained or were placed at 4 0c. 
5.3.5. Immunostaining 
The fixed cells were immunostained for detection of phosphorylated-phospho lamb an (p-
phospholamban) proteins and stained for visualization of f-actin. For detection of p-
phospholamban, the primary and secondary antibodies were p-phosppholamban (Ser 16) 
(sc-12963, Santa Cruz Biotechnology, Santa Cruz, CA)) and FITC-conjugated chicken 
anti-goat (Alexa Fluor 488, Invitrogen, Carlsbad, CA) respectively. Both antibodies 
were diluted (1:100) in 1% BSA. The cells were incubated first with the primary 
antibody at room temperature for 1 h, followed by the addition of the secondary antibody 
for 1 h at room temperature. For f-Atin staining, TRITC-conjugated Phalloidin (1: 1 00; 
Millipore, Billerica, MA) in 0.5% BSA solution was added to the cells and incubated for 
1 h at room temperature. After the staining, light Diagnostics mounting fluid (5013, 
Millipore, Billerica, MA) was added. Phase contrast and fluorescent images were taken 
with the use of a CCD camera connected to a fluorescent microscope (20X, Nikon, 
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Eclipse TE 2000-U). MetaMorph Software Program was used for the analysis of the 
Images. 
5.4. EVALUATION OF CELLS USING MICROSCOPY 
H9c2 cells were cultured in static condition (control) and within the JlCCCM under 
pulsatile pressure and stretch, representing normal physiological loading. Cells cultured 
under flow only were not evaluated, but used just for the reference; therefore, it is not 
discussed in this session. 
Cell cultured in static condition (control) attained a fibroblast like morphology (Fig. 5.3a) 
whereas cells cultured in the JlCCCM were more rectangular, and presented a postage 
stamp-like morphology (Fig. 5.3b). The size of the cells cultured within the JlCCCM 
exposed to pressure was larger than those cultures in static condition. 
Staining with Phaloidin showed low intensity of the fluorescent color and random 
orientation of f-actin in controls in comparison to aligned f-actin in cells cultured with 
pulsatile pressure and stretch (Fig. 5.3c and d). This indicated that the contraction-
stretching of the cells promotes the increasing % of f-actin and also an increase in the 
length of the sarcomere, and helps to align the cells in one direction. The increase in 
length of the sarcomere is the result of the increase in contraction of the cell under 
pulsatile stretch. The alignment of the cells demonstrated that mechanical loading 
spontaneously rearranged the orientation of the cells. 
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P-phospholamban was detected in cells cultured within the /lCCCM, however the 
expression of this protein was very low in cells culture in static condition, as shown is 
Figure 5.3e, in comparison to the cells cultured in /lCCCM (Figure 5.3f). 
Phospholamban is the integral membrane protein. To respond to the contraction of the 
cells, phospholamban is phosphorylated. With cAMP, this p-phospholamban promotes 
the influx ofCa2+ into the cells [61-62] to bind to the contractile unit, causing the cells to 
contract. Therefore, indirectly, the increasing of activation of p-phospholamban, which 
was reflected by the intensive green color on the loading sample in comparison of the 
color on the control sample on the Fig. 5.3e and f, will be indicative of cell contraction. 
5.5. CONCLUSION 
H9c2 cells were cultured within this device to demonstrate proof-of-concept of the ability 
of the /lCCCM to sustain cell culture. The cells not only survived physiological loads in 
vitro but the effects of physiological loading were clearly evident when analyzed via 
mICroscopy. Cells within the /lCCCM established an in-vivo postage stamp -like 
morphology, showed alignment of F-actin stress fibers and increased expression of p-
phospholamban in comparison to static controls. 
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Control Loading 
Figure 5.3. Physiological loading promoted the alignment of f-actin and increased 
phosphorylated phospholamban activity in H9cC2 cells. Cells were under static condition 
(control) and normal physiological loading for 24 hrs. Notice the directional alignment of f-actin 
stress fibers and increased p-phospholamban activity in the loading condition. (a, b) Phase 
contrast images; (c, d) Staining with TRITC-conjugated Phalloidin for detection of f-actin; (e, f) 
Immunofluorescence staining for detection ofp-phospholamban activity; (g, h) Merged images of 
F-actin and p-phospholamban. 
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CHAPTER VI- CONCLUSION AND FUTURE DIRECTION 
CVD continues to be a major healthcare problem worldwide. Current treatment options, 
though beneficial have significant limitations. In order to address these issues and 
provide new treatment options a better understanding of the molecular pathophysiology 
of CVDs is necessary. Cellular level models provide the best platform for discovery 
based studies. However, current approaches for cardiac cell culture fail to accurately 
replicate the mechanical loading conditions seen in-vivo as a consequence of normal 
hemodynamic loading and unloading. Available techniques address mechanical loading 
on an individual basis but to date, no system that accurately replicates the in-vivo 
mechanical loading environment exists. This has resulted in cell-level studies being 
conducted in environments with little or no physiological relevance. 
The ).lCCCM was designed and developed to culture varIOUS cardiac cells in a 
physiologically relevant environment by replicating the mechanical loading conditions 
generated as a consequence of normal hemodynamic loading and unloading. Various 
variables like pressure, strain and shear can accurately replicated in a pulsatile fashion 
similar to conditions experienced in the heart. Characterization studies show that 
mechanical loading profiles associated with normal and various disease conditions of the 
heart including heart failure, hypertension, hypotension, bradycardia and tachycardia can 
be accurately replicated over extended periods of time. Finally, proof-of-concept studies 
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using H9c2 cells, a cardiomyocyte cell line confrrms the ability of this system to culture 
cells within this platform and evaluation of cells using miCroscopy and 
immunofluorescence indicates establishment of an in-vivo like phenotype. 
Thus far, characterization and proof-of-concept demonstrations were accomplished using 
this system. Confirmation of the ability of the ~CCCM to accurately mimic the in-vivo 
cardiac environment allows for the design and study of various conditions associated with 
CVD. These studies include cardiomyocyte regeneration using mechanical loading and 
stem cells, adult cardiomyocyte regeneration using controlled mechanical loads, study of 
cardiac and aortic endothelial cells under conditions of continuous and pulsatile flow and 
finally evaluation of drugs and other treatment options using cardiac cells maintained 
under various disease conditions. 
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A. C H A RAe T E R I Z A T ION 0 F M E M BRA NET Hie K NESS 
The thickness of the membrane was measured using Profilometer Veeco Dektek 8M. To 
obtain different thicknesses, 6 different spinning speeds (200 rpm, 700 rpm, 1000 rpm, 
2500 rpm, 4000 rpm, and 5000 rpm) were performed. For each spinning speed, two 
different PDMS mixtures (ratio 10: 1 w/~ were made at different times. To measure the 
thickness of the PDMS membrane, two or three different locations of the PDMS 
membrane (the edges, the center) on the silicon wafer were measured. Then, the average 
value for each set was calculated as well as the standard deviation (Table A and Fig. A) 
Table A. Membrane thickness obtained at different spinning speeds. 
Spin average 
Speed Membrane thickness thickness STDEV 
rpm !lm !lm !lm !lm !lm !lm !lm !lm !lm 
200 491.21 488.41 514.54 513.55 530.53 455.37 506.66 500.04 24.41 
700 136.84 138.89 137.04 151.13 132.97 133.99 131.3 137.45 6.58 
1000 94.48 94.38 92.76 93.83 83.13 91.07 92.64 91.76 3.98 
2500 35.49 35.29 38.84 36.08 35.99 34.68 34.8 35.88 1.41 
4000 20.41 20.93 22.26 23.3 22.37 21.55 20.24 21.58 1.13 
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B. PUMP FLOW RATE CHARACTERIZTION 
4000 5000 
To know accurately the flow rate delivered by the peristaltic pump for different tubing 
diameter, tJ e pump was calibrated. To calibrate the pump, a flow rate value was set on 
the digital t SPlay of the pump and the volume delivered in 30 seconds was measured. 
For each flow rate set on the pump, four measurements of the volume were performed. 
(Table B and Figure B). 
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Table B. Raw data for the flow rate corresponding to the digital number on the peristaltic pump 
Number Flow rate Flowrate Flowrate Flowrate Average Standard 
on pump 1st 2nd 3rd 4th flowrate Deviation 
mU30sec mU30sec mU30sec mU30sec mU30sec mU30sec 
40 4.350 4.275 4.400 4.245 4.318 0.071 
50 5.273 5.052 5.250 5.104 5.170 0.108 
60 6.220 5.895 6.080 5.626 5.955 0.257 
70 7.305 6.955 7.133 6.853 7.062 0.199 
80 8.092 7.604 8.088 7.438 7.806 0.335 
90 9.162 8.567 9.021 8.380 8.783 0.369 
100 10.077 9.503 9.920 9.272 9.693 0.371 
110 10.488 9.872 10.721 10.224 10.326 0.365 
120 11.314 10.892 11.677 11.125 11.252 0.332 
130 12.900 12.400 12.600 12.100 12.500 0.337 
140 13.511 12.864 13.422 12.479 13.069 0.487 
14 
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Figure B. Flow rates as a function of frequency. 
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C. CELL CULTURE MEDIUM AND SOLUTIONS 
C.1. 1 X PBS (Phosphate Buffered Saline solution) 
For lL of IX PBS solution: 
- 900 mL of de-ionized water (DI water) 
- 100 mL of lOX PBS, pH 7.4 (Fisher Scientific, BP399-l) 
- Mix well and filter with 0.02 !lm filter 
- Store at room temperature 
C.2. 1 X Trypsin Solution 
For 100 mL of IX Trypsin solution: 
- 90 mL of sterilized IX PBS 
- 10 mL of lOX Trypsin (MP Biomedicals, 1689349) 
- Mix well and store at 4 DC, ifused in less than I month, or at -20 DC 
C.3. 0.02% gelatin solution 
For 100 mL of 0.02% Gelatin Solution: 
- 100 mL ofDI water 
- 2.0 mg of gelatin (BD Biosciences, Cat # 214340) 
- Heat at 121 DC in the autoclave for 15 min 
- Coo I and filter. 
- Store at 4 DC 
C.4. Ext racellu la r mat rix sol ution (E C M sol ution) 
For 50 mL ofECM solution: 
- 42.5 mL of 0.02% filtered Gelatin Solution 
- 5.0 mL of Attachment Factor Solution (Genlantis, Cat # PR123100) 
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- 2.5 mL of 1.0 mg ImL Fibronectin solution* (BD Biosciences, 356008) 
- Mix well, aliquot into 15 mL tubes and store at -20 DC 
* Note: reconstitute 5 mg of Fibronectin in DI water to obtain 1 mg ImL 
fibronectin, and dissolve it slowly without agitation, store at -20 DC) 
C.5. H9c2 cell culture medium 
For 555 mL H9c2 cell culture medium: 
500 mL ofDulbeco's Modified Eagles' Medium (DMEM) (Cellogro, 
Cat#1O-013 CV). 
- 55 mL ofHyc1one@ Fetal Bovin Serum (PBS) (Thermo Scientific, Cat# 
SV30014-03) 
- 5.5 mL of Antibiotic Penicillin-Streptomycin Solution (Cellgro, Cat# 
30-002-CI) 
- Mix well and store at 4 DC 
C.6. 4% PFA solution (Paraformaldehyde solution) 
For 40 mL 4% PF A solution: 
30 mL of I X PBS solution 
10 mL of 16% Formaldehyde Solution (Thermo Scientific, 28908) 
Mix well and store at 4 DC 
C.? Washing buffer (0.05% Tween-20 solution) 
For 100 mL of washing buffer: 
- 99.95 mL of IX PBS solution 
- 0.05mL Tween-20 (Fisher Scientific, BP 337-100 ) 
- Mix well and store at 4 DC 
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C.B. 0.1 % Triton X-100 solution 
For 100 mL of 0.1 % TritonX-1 00 solution: 
- 99.9 mL oflX PBS solution 
- 0.1 mL ofTritonX-IOO (Fisher Scientific, BP-151-500) 
- Mix well and store at 4 DC 
c.g. Blocking solution, 0.5% Bovine Serum Albumin (BSA) solution 
For 50 mL of blocking solution: 
- 50 mL of IX PBS solution 
- 0.25 g ofBSA (Sigma, A94I8-lOg) 
- Mix well, filter, and store at 4 DC 
C.10 0.05% Sapronin solution 
For 10 mL of 0.05% sapronin solution: 
- 10 mL of IX PBS solution 
- 5.0 mg of sapronin 
- Mix well, store at 4 DC and use it within a week 
O. CELL CULTURE PROTOCOLS 
0.1 Sterilization 
a. The platform, collapsible valve and tunable valve: 
- Soak the parts in 10% hydrochloride for 10 minutes 
- Rinse well with tap water for 1 minute and dry with tissue 
- Soak in 70% isopropanol for 10 min in the hood and keep the parts 
under sterile conditions 
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- Rinse with IX sterilized PBS before used 
b. The tubes, needles, medium containers: 
Autoclave at 121°C for 15 min 
c. Digital Manometer: 
Remove all old medium inside 
Fill with 70% isopropanol for at least 10 minutes 
Remove all the isopropanol and refill with filtered IX PBS 
Remove all IX PBS and refill fully with filtered IX PBS 
d. Tensile ring and the reservoir: 
Wash with water and let it air dry. 
Use clear tape to remove the particle dust 
Rinse with 70% isopropanol then heat on the hot plate at 115 DC for 10 
minutes 
Keep it in sterile conditions 
e. The cell culture chamber: 
Oxygen plasma and heat at 115 DC (after bonding) was applied 
0.2 Cell cultu re 
Cells were grown in a 25 rnL cell culture flask and split when they were 90-100% 
confluence. All manipulations must be performed inside the cell culture hood. 
- Warm the medium at 37 DC and spray the bottle with 70% isopropanol before 
placing it inside the cell culture hood. 
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- Under a microscope, check if the cells are confluent, contaminated (clear or 
cloudy, tiny particles), and shape of cells. Then transfer the cell culture flask to the cell 
culture hood 
- Remove the old cell culture medium 
- Wash with 5 mL of filtered IX PBS solution, gently swirl and then remove the 
PBS 
- Add 3 mL of IX Trypsin, shake gently, and incubate at 37°C for 4-5 mins to 
detach the cell. To detach the cells faster, tap the bottom of the flash few times after the 
incubating period 
- Neutralize trypsin with 10 mL fresh H9c2 cell culture medium. Pipette up and 
down two or three times gently. Then, transfer all cell suspended solution into a 15 mL 
centrifuge tube. 
- Centrifuge at 1000 rpm for 5 minutes at 25°C. 
- Discard the supernatant and keep the cell pellet 
- Re-suspend the cell pellet with 4 mL fresh cell culture medium. 
- Add 5 mL of medium to the cell culture flash and transfer 0.5 mL of cell 
suspended solution to the flash. Mix one or two times with pipette. 
- Incubate in cell culture incubator (37°C, 5% C02) and change cell culture 
medium for every two or three days. 
- If planning to do the experiment, keep the remaining of cell suspended solution 
for the experiment (see Appendix DA). Otherwise bleach and discard the cell suspended 
solution. 
- Clean up the hood with 70% isopropanol 
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D.3. Preparation of the cell culture chamber 
Two or three days before seeding the cell on the thin PDMS membrane in a cell culture 
chamber of the device, the membrane must be coated with ECM substrate for the cell to 
attach and grow. 
- Apply oxygen plasma (10% oxygen, 100 mmTorr, and 100 mmHg) on the 
membrane for 1 minute 
- Insert a 18G needle into the channel 
- Insert the sterilized tensile ring into the chamber 
- Place the sterilized reservoir on the top of the chamber and press it 
- Add 100 III ofECM solution. 
- For sterilization, apply UV light for 4 minutes. 
- Store the chambers at 4 DC. for 3 days 
- For cell culture, incubate the chambers at 37 DC for 30 min 
D.4. Seed cells in the cell cultu re chamber 
- Count the cells to estimate the total number of cells per mL. 
- Use the formula CIVI = C2V2 to calculate the volume needed to have 2.5 xl04 
cells per chamber 
- Transfer the coated ECM cell culture chambers from the incubator to the hood. 
- Remove the ECM solution and quickly fill the chamber with 200 ilL of cell 
culture medium 
- Remove 125 ilL of medium from the chamber 
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- Add 2.5 x 104 cells suspended in medium into each well 
- Observe the cells under the microscope. Ifthe cells are not distributed 
homogeneously, then pipette gently up and down two or three times 
- Incubate for 4 h or until the cells attach and spread 
- Fill the reservoir with H9c2 cell culture medium (~1.3 to 1.5 mL). 
- Incubate at 37°C. After 1 h, observe the devices and ensure there is not 
leakage 
- Culture the cells for 48 h at 37°C 
- Change medium every 24 h 
0.5. Cell counting and calculation of cell concentration with the use of a 
Cellometer® (Nexcelom Bioscience, CP2-002): 
- Add 20 J..lL of cell suspension into a sample introduction port of the counting 
chamber and wait for one minute. 
- Place Cellometer® under an optical microscope and adjust the microscope to 
visualize the grid line and the cells. 
- Count cells as indicated by the manufacturer. Briefly, count the cells within four 
large squares. For each square, count the cells inside the square plus the cell 
attaching the upper and right edges. 
- Calculate the cell concentration 
The average cells/square = (1/4) x (total cells counted in 4 squares) 
Cell concentration (cells /mL) = 1(/ x (average cells /square) 
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D.6 Immunofluorescence staining 
All the solutions must be warmed at 37°C or at room temperature. For each cell 
chamber: 
Fixed the cells with 200 ilL of warmed 4% PFA solution for 20 mins at RT. 
Wash two times with the warmed washing buffer (250 ilL Ichamber each 
time) 
Permeabilize with 250 ilL of 0.1 % Triton X-I 00 solution for 5 mins at RT. 
Washed two times with washing buffer «250 ilL Ichamber each time) 
Block with 250 ilL blocking solution for 30 mins at RT 
Incubate on a low speed shaker with the primary antibody p-phospholamban 
(Ser 16, 1: 1 00; Santa Cruz Biotechnology, Santa Cruz, CA) in freshly made 
0.05% BSA solution at RT for 1 h 
Wash three times with washing buffer for 5 mins each time at RT 
Incubate on a low speed shaker at RT for 60 min with the second antibody, 
FITC-conjugated chicken anti-goat (1: 1 00; Alexa Fluor 488, Invitrogen, 
Carlsbad, CA) in 0.05% BSA solution. To avoid quenching of the 
fluorescence dye, cover the chamber with aluminum with foil. 
Wash three times with washing buffer, 5 mins each time at RT 
For F-actin detection, incubate at RT for 1 h with TRITC-conjugated 
Phalloidin (l: 1 00; Millipore, Billerica, MA) in blocking buffer. 
Wash three times with washing buffer 
Add 250 ilL of Light Diagnostics mounting fluid (Millipore, Billerica, MA) 
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Examine the cells using a Nikon Eclipse TE2000-U fluorescence microscope, 
20X. 
E. PROGRAM OFTHE HEADWAYSPINNER 
This program is set up to make PDMS membrane at 400 rpm 
- On the program panel, select "Recipe", then enter a program number. 
Press "Step", enter 1, then: 
Press "Step terminate", enter 0.5 sec, press "Enter". 
- Press the 'Speed/Ramp', enter 200 rpm, press "Enter" 
Press the "Speed/Ramp" again, enter 1 00 rpm, press "Enter" Press 
"Step", enter ~ 
Press the "Terminate", enter 30 sec, press "Enter" 
- Press the "Speed/Ramp", enter 400 rpm, press "Enter" 
- Press the "Speed/Ramp" again, enter 200 rpm, press "Enter" 
Press "Step", enter 1. 
Press the "terminate", enter 0.5 sec, press "Enter" 
Press the "Speed/Ramp", enter 200 rpm, press "Enter" 
Press the "Speed/Ramp" again, enter 1 00 rpm, press "Enter" 
Press "Step", enter .Q to exit the program. The system is ready to run. 
F. PROTOCOL TO MAKE THE PDMS THIN MEMBRANE 
Programming the Headway Spinner as Appendix E. 
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Place the wafer on the center of the platform of the spinner and press 
"Vacuum" on the program panel. 
Check the balance of the wafer by spinning the wafer. 
Add PDMS on the center ofthe wafer (~ 5 g or as large as a dollar coin). 
Close the lid. 
Press the green button on the control paddle to start the spinning. 
Wait until the spinner completely stops, open the lid, turn off the vacuum, and 
transfer the PDMS coated wafer to the hot plate. 
Bake at 115°C for 10-15 min, then, cool down the wafer at room temperature. 
G. OPERATING THE ~CCCM SYSTEM 
- Turn on the peristaltic pump 
- Set 15 flow rate on the display of the pump and circulate fluid for 15 min 
- Increase the flow rate by lOon the pump every 10 min to reaches 40 on the 
digital display. Circulate fluid for another 10-15 min. 
- To start the pressure generator, turn on the air supply, then the pulsatile pressure 
generator and wait ~ 1 min. Set the pulsatile pressure generator to 80 bpm and 50% 
systolic. 
- To monitor the pressure, turn on the digital manometer connected to the cell 
chamber 
- Let the system run for 15 min. 
- Increase the pressure in the pressure generator to 15mmHg, then every 15 
minutes, increase the pressure by 15mmHg until it reaches 45mmHg. 
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- Tighten gently the tunable valve to increase pressure slowly. 
Adjust the tunable valve and pressure generator to obtain the desired pressure. 
Every time the pressure is adjusted, wait for 10-15 min for pressure stabilization. 
Note: the pressure generator and tunable valve must be adjusted alternatively to set the 
pressure. When tighten the tunable valve, if the lower pressure is higher than 30mmHg, 
increase the pressure in the pressure generator. If the lower pressure has negative 
values, reduce the pressure in the generator. If the peak pressure increases suddenly, 
release the tunable valve. 
- To stop the system, first, slowly release the tunable valve. Then, reduce the 
pressure in the pressure generator gradually all the way to OmmHg, within30 min. Then, 
turn off the air supply system. Wait for 5 min, then, turn ofthe pressure generator. 
Reduce flow rate and stop the circulation of fluid. 
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